Tumor lysis syndrome during treatment with AMN107 (Nilotinib) in a patient with chronic myelogenous leukemia accelerated phase

J Clin Pharm Ther. 2008 Feb;33(1):91-2. doi: 10.1111/j.1365-2710.2008.00873.x.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Acute Kidney Injury / chemically induced
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Drug Monitoring
  • Humans
  • Leukemia, Myeloid, Accelerated Phase / drug therapy*
  • Male
  • Middle Aged
  • Pyrimidines / adverse effects*
  • Pyrimidines / therapeutic use
  • Tumor Lysis Syndrome / etiology*

Substances

  • Antineoplastic Agents
  • Pyrimidines
  • nilotinib